The GBS Inc. Management Team, Scientific Team and Board of Directors have significant global experience in the development of pharmaceuticals, medical devices and product launches.
Dr Steven Boyages
M.D., MB, BS, Ph.D
Interim CEO and Chairman of the Board
A practicing clinician in endocrinology with more than 30 years’ experience in medicine, including multiple executive positions, Dr. Steven Boyages serves as Chairman of the Board of GBS Inc. Dr. Boyages previously held the position of Chief Executive of the Sydney West Area Health Service (SWAHS), which is now known as Western Sydney Local Health District. Covering a population of 1.2 million people, SWAHS employed more than 15,000 staff and had a gross operating budget of $2 billion (AUD), managing $1.6 billion (AUD) worth of assets. Dr. Boyages has also served as Medical Director for eHealth New South Wales, and was the foundation Chief Executive of the Clinical Education and Training Institute (CETI) New South Wales (NSW), Australia, set up to ensure the development and the delivery of clinical education and training across the NSW public health system.
Previous to this, Dr. Boyages was the Director of Diabetes and Endocrinology at Westmead Hospital, from 1990 to 1999. During this time, Dr. Boyages’ major achievements were to define the pathophysiology of thyroid hormone deficiency on brain development secondary to iodine deficiency; to develop prevention strategies in iodine deficient communities in China, India, Indonesia and Northern Italy; to define the impact of growth hormone excess and deficiency in adults and to develop innovative population health models of care for people with diabetes. Dr. Boyages continues an active research career in a range of fields, but mostly in the pursuit of better models of chronic disease prevention and management.
Dr. Boyages was the foundation director of the Centre for Research and Clinical Policy in NSW Health in 1999, during which he established the Priority Health Programs (receiving $15 million (AUD) in funding per annum), doubled the Research Infrastructure Grants Program, established the Quality Branch of NSW Health and was appointed as Clinical Advisor to the Director General to implement the Government Action Plan for Health Reform. Additionally, Dr. Boyages was instrumental in establishing and securing funding for the NSW biotechnology strategy, BioFirst, a $150 (AUD) million investment.
Mr Spiro Sakiris
B. Bus, Dip Law, CA
Chief Financial Officer
Mr. Sakiris has 34 years’ experience in accounting and taxation, IPOs and capital raising, and business system designs, including the application of IFRS and US GAAP for the life science industry. Mr. Sakiris is a member of the Institute of Chartered Accountants of Australia & New Zealand.
Mr Harry Simeonidis
Mr. Simeonidis has more than 25 years of experience in healthcare, pharmaceutical and life sciences across various senior management positions throughout Asia, Australia and New Zealand. Before joining GBS Inc., he was the General Manager, Surgery, Asia Pacific, at GE Healthcare where he oversaw significant expansion of the business’ market share. Prior to this, Harry spent nine years as the President and CEO of GE Healthcare ANZ. Mr. Simeonidis also serves as non executive Director of Farmaforce Limited, a publicly traded contract sales organization servicing the Australian pharmaceutical industry.
Professor Paul Dastoor
Ph.D, B.A. (Hons)
Prof. Dastoor is a Professor in Physics in the School of Mathematical and Physical Sciences and the Director of the Priority Research Centre for Organic Electronics at the University of Newcastle in Australia. He received his B.A. degree in Natural Sciences from the University of Cambridge in 1990 and his Ph.D. in Surface Physics, also from the University of Cambridge, in 1995. Prof. Dastoor’s expertise covers surface analysis, electron spectroscopy, thin film growth, organic electronics, organosilane chemistry, polymer films, atom beam optics and microscopy and medical devices. His research can be grouped in three main areas: (1) Helium Atom Microscopy, (2) Polymer Adsorption on Metal Surfaces and (3) Organic Electronic Devices. Helium Atom Microscopy Atomic scattering from surfaces has matured into a unique analytical technique for the study of formation of thin film structure
Chair, Audit Committee (Independent)
A Certified Public Accountant with 12 years’ experience in auditing, accounting, and financial reporting in previous roles held at PricewaterhouseCoopers and Pall Corporation, Mr. Towers chairs the Audit Committee for GBS Inc. Mr. Towers is EVP, Chief Accounting Officer and Principal Financial Officer of Newtek Business Services Corp (NASDAQ:NEWT). His expertise includes auditing, SEC reporting, US GAAP, experience in leading equity and debt raisings, due diligence on business mergers and acquisitions, SOX compliance, FP&A, treasury, and tax. He holds a Bachelor of Science from Hofstra University and is a member of the American Institute of Certified Public Accountants. Mr. Towers brings to the Board expertise in financial reporting to capital markets and an understanding of compliance and the audit process.
Member, Audit Committee (Independent)
A securities lawyer in New York City for more than 40 years, Lawrence is a graduate of Columbia College and Columbia University Law School, and a Research Fellow of the London School of Economics. Lawrence has extensive experience representing public companies and investment banking firms in connection with Initial Public Offerings. During his career, Mr. Fisher was a partner at Orrick, Herrington & Sutcliffe law firm for 11 years, at Kelley, Drye & Warren lawfirm for 10 years, and Parker, Chapin & Flattau, serving on all firms’ Executive Committees. Lawrence has held various Board positions, including Financial Federal Corporation (NYSE), National Bank of New York City and Viking Energy Group. Mr. Fisher brings to the Board his vast experience as a lawyer in the field of capital markets.
Dr George Margelis
Dr. Margelis is a medical practitioner with 30 years’ experience. Dr. Margelis was Chief Information Officer of Macquarie Health Corporation where he led a team producing online health applications. He has worked at Intel and the Intel-GE Innovation spin-off and was also senior adviser to HIMSS, the international peak body for health technology. Dr. Margelis is currently Adjunct Associate Professor at the University of Western Sydney with the TeleHealth Research & Innovation Laboratory (THRIL) and a member of Ignition Labs.
Mr Jonathan Hurd
Mr. Hurd has been a member of the GBS Inc. Board of Directors since April 2018, serving as our Chairman of the Board from August 2018 to November 2019. Mr. Hurd has expertise in broker-dealer and investment advisory regulations and is experienced in FINRA and SEC rules and regulations. Mr. Hurd has served as Founder and CEO at Asgard Regulatory Group, or “Asgard,” since founding the firm in 2008. Mr. Hurd was also a Supervisor of Examiners at FINRA, previously NASD, in the New York District Office. While with FINRA, he supervised routine examinations of FINRA member firms, and conducted large-scale enforcement cases jointly with the Justice Department and Federal Bureau of Investigations. Mr. Hurd is also a Certified Anti-Money Laundering Specialist (CAMS) and holds the Series 7, 24, 27, 53, 55, 63, 66, 79 and 99 licenses as well as his NYS Life and Health Insurance licenses.